UCB now has approval for its new epilepsy drug Briviact on both sides of the Atlantic after a green light from the US FDA. The US regulator has given the go-ahead to Briviact (brivaracetam) as an add-on treatment to other medications to treat partial ...
By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.
By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.